RT Journal Article
SR Electronic
T1 The International Dermatology Outcome Measures Initiative as Applied to Psoriatic Disease Outcomes: A Report from the GRAPPA 2013 Meeting
JF The Journal of Rheumatology
JO J Rheumatol
FD The Journal of Rheumatology
SP 1227
OP 1229
DO 10.3899/jrheum.140176
VO 41
IS 6
A1 Alice B. Gottlieb
A1 April W. Armstrong
A1 Robin Christensen
A1 Amit Garg
A1 Kristina Callis Duffin
A1 Wolf-Henning Boehncke
A1 Joseph F. Merola
A1 Dafna D. Gladman
A1 Philip J. Mease
A1 Robert A. Swerlick
A1 Cheryl F. Rosen
A1 April Abernethy
YR 2014
UL http://www.jrheum.org/content/41/6/1227.abstract
AB In the United States, access to care is the number one issue facing our patients with dermatological conditions. In part, this is because we do not have outcome measures that are useful in clinical practice and available in databases where payers and governmental agencies can compare the performance of physicians and treatments. There is a growing recognition that insufficient attention has been paid to the outcomes measured in clinical trials and subsequently in clinical practice. The International Dermatology Outcome Measures group includes all willing stakeholders: patients, physicians, payers, and pharmaceutical scientists. As reported herein, the group’s goal is to develop outcome measures in dermatology that address the needs of all involved.